Showing 1765 results
-
Press release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Press release /Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the…
-
Press release /If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
-
Press release /55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on…
-
Press release /Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
-
Press release /Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL…
-
Press release /More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
-
Ad hoc release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)…
-
Press release /Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Ad hoc release /Basel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von…